News stories about Sensus Healthcare (NASDAQ:SRTS) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sensus Healthcare earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.5695184036668 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several research firms have weighed in on SRTS. began coverage on Sensus Healthcare in a research report on Friday, July 6th. They issued a “buy” rating and a $12.25 price objective on the stock. ValuEngine raised Sensus Healthcare from a “hold” rating to a “buy” rating in a research report on Monday, May 7th. Finally, Roth Capital started coverage on Sensus Healthcare in a research report on Wednesday, August 1st. They set a “buy” rating and a $12.50 price target on the stock. Four research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $11.25.

Sensus Healthcare traded down $0.31, hitting $7.16, on Friday, according to The company’s stock had a trading volume of 35,716 shares, compared to its average volume of 21,902. Sensus Healthcare has a 52-week low of $4.31 and a 52-week high of $7.71. The stock has a market cap of $101.35 million, a P/E ratio of -25.57 and a beta of -1.37. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.65 and a current ratio of 3.90.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, August 2nd. The company reported ($0.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01). The business had revenue of $6.06 million during the quarter, compared to the consensus estimate of $6.36 million. Sensus Healthcare had a negative return on equity of 26.19% and a negative net margin of 13.07%. sell-side analysts predict that Sensus Healthcare will post -0.17 earnings per share for the current year.

In related news, CTO Kalman Fishman sold 4,767 shares of Sensus Healthcare stock in a transaction on Wednesday, June 20th. The stock was sold at an average price of $7.52, for a total transaction of $35,847.84. Following the transaction, the chief technology officer now directly owns 955,023 shares in the company, valued at $7,181,772.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joseph C. Sardano sold 7,945 shares of the business’s stock in a transaction dated Wednesday, June 20th. The shares were sold at an average price of $7.52, for a total value of $59,746.40. Following the completion of the transaction, the chief executive officer now owns 1,578,349 shares in the company, valued at $11,869,184.48. The disclosure for this sale can be found here. Insiders have sold 60,657 shares of company stock worth $456,136 over the last quarter. 41.10% of the stock is owned by company insiders.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Further Reading: What does earnings per share mean?

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with's FREE daily email newsletter.